Open navigation

Media Center

Press Releases

Neon Therapeutics and Bristol-Myers Squibb Enter Clinical Trial Collaboration

Neon Therapeutics Enters License Agreement with the Broad Institute,  Dana-Farber Cancer Institute and Massachusetts General Hospital

Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies

Publications

Founders' & Advisors' Publications

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

N.A. Rizvi, P. Kvistborg, T.N. Schumacher, et al. SCIENCE. 2015


Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens

M.M. Gubin, T.N. Schumacher, R.D. Schreiber, et al. NATURE. 2014


Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

R.S. Herbst, H.E. Kohrt, et al. NATURE. 2014


Neoantigens in cancer immunotherapy

T.N. Schumacher, R.D. Schreiber. SCIENCE. 2015


Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines

N. HacohenE.F. Fritsch, T.A. Carter, et alCANCER IMMUNOLOGY RESEARCH. 2013

 

Neon Team Publications

Molecular and genetic properties of tumors associated with local immune cytolytic activity

M.S. Rooney, C.J. Wu, N. Hacohen, et al. CELL. 2015


Biomarkers in Cancer Immunotherapy

T.N. Schumacher, M.M. van Buuren, et al. CANCER CELL. 2015


High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Linneman, M.M. van Buuren, T.N. Schumacher, et al. NATURE MEDICINE. 2015


Personal neoantigen cancer vaccines: The momentum builds

E.F. Fritsch, N. Hacohen, C.J. WuONCOIMMUNOLOGY. 2014


HLA-binding properties of tumor neoepitopes in humans

E.F. Fritsch, M. Rajasagi, P.A. Ott, et alCANCER IMMUNOLOGY RESEARCH. 2014